This is a working overview of LC-MS, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-02-28. Anything still debated is marked as such rather than presented as settled.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| Molecular weight | 437.9 g/mol | Calculated from the formula |
| Primary target | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian regulation |
| Solubility | Soluble in DMSO and ethanol | Poorly soluble in water |
| Typical storage | -20 °C, desiccated | Protect from light and moisture |
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
==== Canaloplasty ==== Canaloplasty is a nonpenetrating procedure using microcatheter technology. To perform a canaloplasty, an incision is made into the eye to gain access to the Schlemm's canal, similarly to a viscocanalostomy. A microcatheter will circumnavigate the canal around the iris, enlarging the main drainage channel and its smaller collector channels through the injection of a sterile, gel-like material called viscoelastic. The catheter is then removed, and a suture is placed within the canal and tightened. By opening the canal, the pressure inside the eye may be relieved, although the reason is unclear, since the canal (of Schlemm) does not have any significant fluid resistance in glaucoma or healthy eyes. Long-term results are not available.
Clathurellinae was split into three families: Borsoniidae (also including species from Turridae), Mitromorphidae and Clathurellidae (all previously lumped under the Turridae). Conorbiinae was raised to the rank of family Conorbidae, consisting of three genera: Artemidiconus da Motta, 1991, Benthofascis Iredale, 1936, and Conorbis Swainson, 1840. Mangeliinae and Oenopotinae were combined and raised to the rank of family Mangeliidae, which had previously been lumped in the Turridae). Raphitominae was raised to the rank of family Raphitomidae (also previously lumped in the Turridae). The classification by Bouchet et al. (2011) was based on mitochondrial DNA and nuclear DNA testing, and built on the prior work by J.K. Tucker & M.J. Tenorio (2009), but did not include fossil taxa. Molecular phylogeny, particularly with the advent of nuclear DNA testing in addition to the mDNA testing (testing in the Conidae initially began by Christopher Meyer and Alan Kohn), is continuing on the Conidae.
== History == The importance of TNF in the development of rheumatoid arthritis was originally demonstrated by George Kollias and colleagues in proof of principle studies in transgenic animal models. Infliximab was developed by Junming Le (b. 1940) and Jan Vilček (b. 1933) at New York University School of Medicine and in collaboration with Centocor (now Janssen Biotech, Inc.).
In July 2012, the government made a review of the mandatory death penalty applied to certain drug trafficking or murder offences. In the midst of this review, a moratorium was imposed on all the 35 pending executions in Singapore at that time (7 for murder and 28 for drug trafficking). During that period of the review of the mandatory death penalty, one convicted murderer, Pathip Selvan s/o Sugumaran, who made headlines for the violent murder of his girlfriend in 2008, won his appeal in October 2012 and was re-sentenced to 20 years' imprisonment for culpable homicide. Wang Zhijian, a Chinese national who committed the 2008 Yishun triple murders, was sentenced to death for a conviction of murder under Section 300(a) of the Penal Code in November 2012, and another unnamed death row convict died of natural causes while in prison. In November 2012, capital punishment laws in Singapore were revised such that the mandatory death penalty for those convicted of drug trafficking or murder was lifted under certain specific conditions. Judges were empowered with the discretion to sentence such offenders to life imprisonment with the possibility of parole after 20 years. These changes were approved by Parliament and set to take effect in January of the following year. In January 2013, the law was again amended to make the death penalty no longer mandatory for certain capital offences.
== List of specialties recognized in the European Union and European Economic Area == The European Union publishes a list of specialties recognized in the European Union, and by extension, the European Economic Area. There is substantial overlap between some of the specialties and it is likely that for example "Clinical radiology" and "Radiology" refer to a large degree to the same pattern of practice across Europe.
Sources: en.wikipedia.org
Methoclocinnamox (MCCAM; developmental code name NIH-10420) is a selective pseudo-irreversible partial agonist of the μ-opioid receptor (MOR). It shows a mixture of opioid agonist- and antagonist-like effects. The drug has long-lasting effects and is insurmountable by other MOR ligands. MCCAM was derived from clocinnamox (CCAM), was first described by 1995, and was of interest in the potential treatment of opioid dependence. However, it was not further developed and was never marketed. A close analogue of MCCAM, methocinnamox (MCAM), which in contrast to MCCAM acts as a MOR pseudo-irreversible antagonist, was first described in 2000 and is under development for the treatment of opioid use disorder and opioid overdose as of 2023.
== Medical uses == Levodopa crosses the protective blood–brain barrier, whereas dopamine itself cannot. Thus, levodopa is used to increase dopamine concentrations in the treatment of Parkinson's disease, parkinsonism, dopamine-responsive dystonia and Parkinson-plus syndrome. The therapeutic efficacy is different for different kinds of symptoms. Bradykinesia and rigidity are the most responsive symptoms while tremors are less responsive to levodopa therapy. Speech, swallowing disorders, postural instability, and freezing gait are the least responsive symptoms. Once levodopa has entered the central nervous system, it is converted into dopamine by the enzyme aromatic l-amino acid decarboxylase (AAAD), also known as DOPA decarboxylase (DDC). Pyridoxal phosphate (vitamin B6) is a required cofactor in this reaction, and may occasionally be administered along with levodopa, usually in the form of pyridoxine. Because levodopa bypasses the enzyme tyrosine hydroxylase, the rate-limiting step in dopamine synthesis, it is much more readily converted to dopamine than tyrosine, which is normally the natural precursor for dopamine production. In humans, conversion of levodopa to dopamine does not only occur within the central nervous system. Cells in the peripheral nervous system perform the same task. Thus administering levodopa alone will lead to increased dopamine signaling in the periphery as well. Excessive peripheral dopamine signaling is undesirable as it causes many of the adverse side effects seen with sole levodopa administration.
Action – Batman: Arkham City Artistic Achievement – Rayman Origins Audio Achievement – Battlefield 3 Best Game – Portal 2 Debut Game – Insanely Twisted Shadow Planet Family – LittleBigPlanet 2 Game Design – Portal 2 Game Innovation – LittleBigPlanet 2 Mobile & Handheld – Peggle HD Online – Browser – Monstermind Online Multiplayer – Battlefield 3 Original Music – L.A. Noire Performer – Mark Hamill (as The Joker, Batman: Arkham City) Sports/Fitness – Kinect Sports: Season Two Story – Portal 2 Strategy – Total War: Shogun 2 BAFTA Ones To Watch Award (in association with Dare to Be Digital) – Tick Tock Toys GAME Award of 2011 – Battlefield 3 Special – Markus Persson
As of 2017, the Panda Restaurant Group had annual sales of over $3 billion and close to 39,000 employees. The Cherngs also opened Panda Innovation Kitchen in Pasadena with their daughter, Andrea Cherng, overlooking a majority of the restaurant's business. The idea for Panda Innovation Kitchen is to experiment with new flavours and ingredients to come up with new menu items. In addition, they also opened a tea bar to introduce Taiwanese drinks such as boba milk tea and new drinks like the Fortune Cookie Shake.In December 2017, Panda Express had opened the chain's 2,000th location, which is located in New York City near Columbia University. In February 2022, Panda Restaurant Group filed a U.S. trademark application for the name PANDAVERSE for "downloadable virtual goods, namely, food items and beverages for use in virtual worlds" and "virtual food and beverage products." The filing marked an intention to expand the Panda Express brand into the Metaverse. In March 2022, Panda Express committed to transitioning to 100% cage-free eggs, responding to pressure from animal welfare groups.
Sources: en.wikipedia.org
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.
It binds to REV-ERBα and REV-ERBβ, nuclear receptors involved in circadian and metabolic gene regulation. This can alter transcription of genes related to lipid and glucose metabolism in experimental models.
No controlled human trials have established that effect. Endurance findings come primarily from rodent studies, and human responses remain unknown.
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.